Read the forces.
Design the response.
My analysis of healthcare markets, delivery models and capital allocation: the economics behind an opportunity, the trade-offs it creates and the evidence required to act.
The CFO Economics
of Accountable Access
Medical margin, risk, capital allocation, and enterprise value. A ten-chapter framework connecting the healthcare dollar to the operating capabilities that make access accountable.
Read the full analysisOptimize for population benefit, not the visible cost curve.
I examine population-health allocation through unmet need, intervention benefit, delivery capacity and the people poorly represented in claims.
VALUE-BASED CARE & RISK ECONOMICSA shared-savings payment is not the same as value created.
Underwrite patient outcomes, provider economics and payer spending separately. Then reconcile the contract, the counterfactual and the cash required to sustain care.
WHOLE-CARE ORCHESTRATION & AIOwn the unresolved handoff.
My whole-care framework connects clinical care, pharmacy, behavioral health, social support and financing through accountable handoffs.
The complete editorial record
Refine your search ↑Biosimilar Strategy: Capture Value Across the Benefit and the Clinic
Lower biologic acquisition prices create an opportunity, but the allocation of that value depends on reimbursement, patient cost sharing, clinical workflow and supplier durability. A biosimilar strategy should reconcile all four before announcing savings.
Cell and Gene Therapy Readiness: Financing the Complete Care Pathway
An outcomes contract becomes useful only when a patient can reach treatment and the parties can verify what follows. Cell and gene therapy readiness should connect eligibility, care capacity, supportive services, liquidity and longitudinal evidence within one accountable pathway.
Drug Shortage Resilience Is a Capital Allocation Decision
Reliable medicine supply has an economic value that a unit-price comparison cannot fully describe. Resilience investment should be targeted to clinical criticality, replacement difficulty and shared upstream risk, with inventory and manufacturing commitments evaluated against realistic disruption scenarios.
Food-as-Medicine Contracts Should Buy Nutritional Persistence, Not Enrollment
The newest trials make the purchase decision more specific. A culturally tailored heart-failure intervention improved short-term utilization outcomes, while other trials did not establish every assumed benefit. Buyers should contract for a defined clinical population, usable nutrition and sustained follow-through, with an evaluation design that can distinguish incremental value from improvement that would have happened anyway.
Rural Health Transformation Is a Capacity and Capital Strategy
Rural Health Transformation funding creates an unusual investment window. Its durable value depends on staffing, reachable services, referral agreements and operating revenue after grants expire. The priority is an accountable regional delivery network in which digital infrastructure supports real clinical capacity and local governance.
Women's Midlife Health Needs an Integrated Delivery Strategy
Midlife health is a delivery opportunity that spans symptom relief, prevention, sleep, behavioral care and work participation. Updated clinical guidance and 2026 FDA labeling changes raise the standard for informed treatment discussions. Employers and providers should build a coordinated pathway with private access and outcome evaluation rather than promise a universal productivity return.
AI Clinical Trial Recruitment: Build Representative Enrollment, Not a Larger Eligibility Queue
AI can expand the set of patients considered for research while making screening faster. The executive challenge is converting that technical improvement into representative, consented, retained enrollment within real site capacity. A recruitment program should be underwritten as a pathway with accountable handoffs, an auditable eligibility record, and funded participation support.
Imaging AI Economics: The Investment Case Runs from Detection to Completed Treatment
Recent randomized mammography evidence strengthens the case for carefully designed AI-supported screening. It also makes a sharper executive question possible: what happens after the improved read? The investable pathway includes diagnostic confirmation, patient contact, specialist capacity, appropriate treatment, and ongoing safety monitoring. Its returns depend on completing that pathway rather than accumulating detected findings.
Digital Quality Measurement Is Contracting Infrastructure: Build the Evidence Before the Score
Digital quality measurement can give providers and payers a more consistent view of care, but a standard interface does not guarantee a trustworthy score. The strategic asset is a reusable evidence layer: governed identities, clinical events, measure versions, provenance, and explainable exceptions. That foundation can support improvement and contracting while making the remaining measurement work visible.
Medicaid eligibility is becoming a continuity strategy
The coming Medicaid eligibility changes create a joint operating challenge for states, health plans, providers and pharmacies. A defensible strategy connects renewal evidence to the care episode, distinguishes an unresolved administrative task from a substantive eligibility determination, and measures continuity without manufacturing eligibility or overstating savings.
The Part D redesign has to reach the medication journey
Part D's richer protection changes the financing of covered medicines. Realizing its value requires a medication journey that distinguishes annual financial exposure, cash-flow timing, coverage restrictions and reliable delivery. The commercial opportunity is a payer-provider-pharmacy continuity service whose outcomes and cost attribution can be audited.
Post-acute capacity is an episode portfolio
Post-acute strategy should manage usable clinical capability across settings rather than a list of referral destinations. A hospital, payer and receiving network can contract around an episode with confirmed capacity, reliable information, medication access and recovery outcomes. The investment question is where an additional capability improves the entire transition.
GLP-1 Cardiorenal Economics: Underwrite the Treatment Pathway Before the Outcome Contract
The expansion of incretin evidence creates a serious prevention opportunity and a difficult financing problem. My thesis is that a payer or integrated delivery system should first establish an indication-specific treatment and measurement pathway, then decide which outcomes it can responsibly contract against. Clinical efficacy, affordability and near-term cash savings belong in separate ledgers.
Precision CKM Care: Allocate Capital to the Pathway Gap, Not Just the Risk Score
Cardiovascular-kidney-metabolic care calls for decisions across clinical specialties, pharmacy, financing and social support. My thesis is that precision includes the ability to deliver a suitable intervention, not merely the ability to rank risk. Capital should target the specific pathway failure preventing clinically justified care while preserving access for patients who require more effort to reach.
Genomic Kidney Care: Invest in Decision Yield, Not Test Volume
Kidney genetics can change the understanding of disease, but a molecular finding is only one stage in a care pathway. My thesis is that a genomic kidney service should be funded and evaluated around documented clinical decisions, with distinct measures for diagnostic yield, changed management and patient outcomes. Recent studies support utility while leaving important causal and financial questions open.
Precision Oncology’s Next Investment Is the Pathway Between the Report and Treatment
Recent evidence supports genomically matched treatment in selected advanced cancers, but a report is only an intermediate product. Service-line investment should target the measured losses between testing, interpretation, patient discussion and feasible treatment.
Hospital at Home Must Buy Community Capacity Before It Can Release Hospital Capacity
Recent trials make a credible case for selected patients receiving acute care at home, but they do not make savings automatic. The operating decision is whether a health system can finance reliable community care and turn released hospital capacity into measurable value.
The Postpartum Handoff Is a Business Model: Pay for Continuity Beyond Delivery
Recent evidence supports a practical investment thesis for women's health: fund the transfer from maternity services into continuing care, and judge monitoring by the decisions it enables. The first-year business case should stand on completed transitions and measured blood pressure outcomes, with long-term savings treated as an unproven upside.
Dementia Care Needs a Capacity Contract: Finance the Household, Not Just the Referral
Trials and workforce studies challenge the assumption that more navigation automatically lowers burden or spending. A durable home-care business should purchase reliable response capacity, track family time alongside formal costs, and make the distinction between societal value and cash savings explicit.
Obesity Pharmacotherapy Is Becoming a Continuity Business
Recent maintenance and discontinuation evidence changes the commercial unit of obesity care: the valuable product is a durable, clinically supervised treatment pathway. Payers and pharmacy operators should measure continuity, patient burden and total episode cost before treating prescription volume as success.
Kidney Prevention Belongs in the Capital Plan Before the Next Dialysis Expansion
Recent kidney research strengthens the case for identifying risk and delivering longitudinal prevention. The capital-allocation challenge is to finance that capability without treating biomarker improvement as booked dialysis savings or weakening capacity for people who already need kidney replacement therapy.
Ambient AI needs a workflow-specific purchase decision.
A randomized scribe trial makes the buying question more precise: which tool improves which part of the work, for which clinicians, at what total cost?
The target variable is a resource-allocation decision.
A foundational algorithm audit shows why a model can predict spending accurately while directing care-management resources away from people with greater need.
A larger training set does not validate every home.
Recent sleep research illustrates the distance between respiratory-model performance, radar measurement and a dependable home-care service.
A benefit offer is only the beginning of an intervention.
A produce-prescription trial sharpens the investment case for social care: define benefit uptake, delivery costs and the outcome being purchased.
Behavioral-health integration needs a plan for month thirteen.
Longer follow-up from a collaborative-care trial shifts the operating question from initial engagement to sustained improvement and a practical route back into treatment.
Pharmacy value depends on the barrier being removed.
A recent discharge trial and a foundational coverage trial show why medication access, transition safety and utilization savings need distinct investment cases.
A longer savings horizon still needs an access test.
Longitudinal ACO evidence supports patient capital, while leaving leadership responsible for quality, equitable access and the participant's own economics.
Integration should earn its place at the handoff.
Hospital-operated Medicare Advantage evidence shows why network strategy needs an episode-level account of utilization, outcomes and the value of ownership.
Productivity becomes value only when the operating model changes.
Workplace evidence suggests that AI can spread useful expertise unevenly. Healthcare leaders still need to demonstrate how that benefit survives review, handoffs and the commercial contract.
The therapy has to reach the person.
Pharmacy belongs at the center of whole-care design: connecting an appropriate treatment decision to access, safe use, monitoring and a sustainable economic model.
Integration is a clinical operating model.
A population approach to behavioral health connects access, treatment, systematic follow-up and clinical authority—and funds the work between appointments.
The referral needs somewhere to go.
My social-care framework connects person-defined needs, available services, community-partner economics and the distribution of benefit.
The signal is not the social need.
Radio and Wi-Fi sensing can contribute to a care pathway. The strategic value depends on validated measurement, confirmed context and a team able to respond—not on inferring a person’s life from ambient data.
What recent research changes about healthcare strategy.
An original executive synthesis of six 2025–2026 journal articles on integration, population health, value-based care and clinical AI.
Optimize for population benefit, not the visible cost curve.
I examine population-health allocation through unmet need, intervention benefit, delivery capacity and the people poorly represented in claims.
A shared-savings payment is not the same as value created.
Underwrite patient outcomes, provider economics and payer spending separately. Then reconcile the contract, the counterfactual and the cash required to sustain care.
Own the unresolved handoff.
My whole-care framework connects clinical care, pharmacy, behavioral health, social support and financing through accountable handoffs.
AI creates capacity. Strategy determines its value.
The enterprise case begins after a task gets faster: what changes in care, whose work remains, which costs disappear and who retains the economic benefit.
Capital should buy evidence before it buys permanence.
An investment thesis becomes useful when it specifies which uncertainty to resolve, what commitment to make now and what evidence earns the next allocation.
Who creates value—and who gets to keep it?
Healthcare strategy begins with the distribution of power: who controls access, who sets the economic terms, who bears the risk and who can credibly choose another path.
The CFO Economics of Accountable Access
A CFO framework for medical margin, risk, capital allocation and enterprise value. New York 2026–2030.
After the AI Pilot: Who Owns the Healthcare Operating Model?
A whole-system reading of AI adoption, pharmacy access, interoperability, capital, and human oversight. The next mandate is an operating journey, not another isolated pilot.
The Healthcare AI Control Plane: Designing the Whole System
I propose an architecture for coordinating care, coverage, pharmacy and payment across institutional boundaries. Its purpose is to carry the context, permissions and accountability needed to complete a decision—and to expose where the next step has no funded owner.
The Healthcare AI Value Realization Ledger
Measure healthcare AI value after implementation, human review, exceptions and transferred workload, with explicit cash and capacity reconciliation.
The ACCESS Model Turns Digital Health Into Reimbursed Care Infrastructure
CMS has opened an outcome-aligned payment path for technology-supported chronic care. The strategic question is no longer whether digital care can engage patients, but whether it can integrate, measure outcomes, and operate inside Medicare workflows.
The 2027 Physician Fee Schedule Makes Provider Economics a Product Requirement
A provider-economics analysis of the proposed 2027 fee schedule: segment payment models, price implementation and test how practices capture value.
Telehealth Extension Gives FQHCs Time to Build a Better Hybrid Care Model
Federal telehealth extensions through 2027 create operating runway for FQHCs and their partners. The next advantage will come from hybrid access, capacity, behavioral health integration, referral completion, and patient continuity rather than virtual visits alone.
Software as a Medical Service Changes the Reimbursement Conversation
CMS is proposing an interim approach for software-based medical services with algorithmic analysis. The opening is important, but the category will reward products that can prove incremental clinical value, cost, workflow fit, and auditable use.
Kidney Payment Reform Still Depends on Referral and Intake Operations
The Kidney Care Choices Model has shown quality gains and spending pressure at the same time. The operating lesson is direct: payment design cannot deliver coordinated kidney care unless referral, education, intake, modality choice, and handoffs work reliably.
Interoperability Is Becoming Commercial Distribution Infrastructure
Evaluate healthcare interoperability through reusable implementation, accountable data-to-action workflows and the cost of ongoing reconciliation.
Healthtech Capital Is Buying Operating Leverage, Not AI Labels
Digital health capital is concentrating in fewer, larger bets while AI becomes expected infrastructure. The durable moat is the ability to translate technology into distribution, workflow adoption, measurable value, and repeatable economics.
Healthcare AI Product Strategy Starts With the Regulatory Boundary
FDA activity around non-device software and clinical decision support makes one product decision unavoidable: define what the software does, who uses it, what evidence they can independently review, and where the function crosses into regulated device territory.
Healthcare AI Buyers Will Test the Claim, Not the Demo
Recent FTC activity around AI accuracy reinforces a broader healthcare buying rule: every performance, autonomy, savings, and workflow claim needs a defined context, evidence trail, limitation, owner, and monitoring plan.
Health-App Data Governance Is Part of the Commercial Product
FTC health-breach guidance makes a practical point for digital health: privacy, data flows, vendors, consent, incident response, and deletion are not legal appendices. They shape buyer trust, implementation, and product architecture.
AI Voice Is Moving Inside the RCM System of Record
A new acquisition signal shows AI voice moving from point solution to embedded revenue-cycle infrastructure. The winning design will connect payer calls, claim follow-up, authorization, evidence, human review, and financial proof inside the core workflow.
340B Is Becoming a Claims-Data Operating Problem
CMS's proposed Part D claim-level data requirements make 340B traceability a cross-functional operating issue spanning pharmacy, provider, claims, contract pharmacy, finance, compliance, and rebate workflows.
What a Healthcare AI Consultant Should Actually Build
A practical operating model for healthcare AI consulting across use-case strategy, workflow discovery, product and data architecture, build-versus-buy decisions, governance, implementation, adoption, and proof.
How Health Plans Should Evaluate AI-Native and Rules-Based Payment Integrity Vendors
A payer decision framework for evaluating AI-native, machine-learning, and rules-based payment integrity vendors across savings quality, explainability, provider abrasion, appeals, workflow, governance, and implementation cost.
Agentic Revenue Integrity Needs a Control Plane
How agentic revenue integrity connects prior authorization, claims, denials, payment integrity, evidence, human review, and financial proof without turning consequential healthcare decisions into black-box automation.
Care Orchestration Contracts: Separate Delivery from Claimed Savings
A public operator brief on why the latest healthtech signal is not just more AI or more access rhetoric, but a harder market demand for proof-bearing orchestration: regulated payment rails, managed care distribution, and referral workflows now need to show measurable execution instead of promising eventual coordination.
Healthcare Investment Diligence: Test the Promise Against Delivery
A public operator brief on why the freshest healthtech signal is not just more policy churn or more AI rollout, but a harder market demand for operating guarantees: if a network, workflow, or automation cannot prove access, compliance, reimbursement durability, and system-fit, buyers are treating it as risk.
Healthcare Navigation: Underwrite the Transition
A public operator brief on why the newest healthcare signal is not just more policy churn or more AI rollout, but a repricing of the navigation layer: CMS is formalizing digital operating control, payer distribution is getting harsher, behavioral telehealth remains a durable demand channel, and providers are buying specialty AI as workflow replacement infrastructure.
Administrative Access: Connect Coverage, Resolution and Cash
A public operator brief on why the latest market signal is not more healthcare AI noise, but a hardening of the front door: CMS is centralizing health-tech product power, exchange markets are getting thinner and more contested, patient-finance AI is being judged on operating proof, and commercialization is moving deeper into policy rails.
Provider AI Economics: Distinguish Productivity from Payment Transfer
A public operator brief on why the newest healthtech signal is not just AI adoption but proof infrastructure: CMS is organizing around products, Medicare Advantage denials are drawing sharper scrutiny, payers are pricing AI coding intensity into next year, and commercialization is getting more policy-native.
Payment Disputes and Care Coordination: The Cost of Resolution
A public operator brief on why healthcare AI and healthtech GTM are shifting from feature demos to auditable operating infrastructure across IDR, electronic prior authorization, AI-first virtual care, RCM, and payer intelligence.
Prior Authorization Is Becoming API Infrastructure
I distinguish prior-authorization API compliance from workflow value, tracing request completion, exception cost and payer-provider workload.
Payment Integrity Is Moving From Audit Function to AI Operating Layer
I evaluate payment-integrity AI through substantiated decisions, net retained value, appeal outcomes, contract incentives and provider burden.
Healthcare AI Search Is Changing Buyer Discovery
Build healthcare discovery around original analysis, attributable experience and accessible evidence that helps buyers evaluate a commercial position.
Agentic RCM Needs Governance, Not More Automation Claims
A financial governance framework for agentic revenue cycle: allocate authority, price review and reconcile recovered revenue separately from faster collection.
Automated Healthcare Administration: The Economics of Verification
A public GTM brief on why healthcare’s next operational winners will look less like “AI tools” and more like regulated infrastructure: CMS is hardening ePA and patient-facing data rails, HHS is turning audits into an AI-supported enforcement motion, and payers are being forced to price the downstream impact of provider AI adoption.
Healthcare AI Infrastructure: Price the Responsibilities That Remain
A public GTM brief on why healthcare’s next AI winners look less like chatbots and more like infrastructure: sensorized hospital rooms, agentic workflow builders inside the EMR, privacy-preserving compute for trial access, and a growing political fight over AI-driven prior auth in Medicare.
Benefits AI: Reliable Identity, Coverage and the Next Action
A public GTM brief on the trust layer forming in healthcare: CMS is turning prior auth into a networked workflow, payers and employers are industrializing AI for navigation and benefits ops, and identity is becoming the new security perimeter for interoperability.
Healthcare Platform Growth: Which Costs Actually Fall with Scale?
A public market brief on today’s operating reality: affordability volatility is turning into a churn tax, provider admin platforms are consolidating into workflow operating systems, and virtual care winners are attaching to payer economics—then staffing up to deliver.
Coverage Volatility: The Cost of Acting on Stale Information
A public market brief on the quiet rebuild underway: coverage churn is becoming an operating risk, electronic prior auth is turning into shared infrastructure, and AI only wins in healthcare when it ships with traceability and contestability.
Electronic Authorization: Finance Reliability and the Right to Challenge
A public market brief on why electronic prior authorization is no longer a compliance project: CMS is forcing cross-ecosystem integration, AI in utilization management is colliding with consumer protections, and "proof + auditability" is becoming the real product for regulated healthcare software.
Claims Intelligence: From Flagged Exposure to Collectible Cash
A public market brief on the new admin arms race: providers are finally buying payer-behavior intelligence like it's a revenue line, payers are demanding governance and defensibility from AI-enabled workflows, and CMS is tightening the front door with data-driven program integrity - pushing healthtech GTM from "automation" to "audit-ready operating systems."
Prior Authorization Readiness: The Economics of the Remaining Work
A public-facing market brief on why CMS is turning electronic prior authorization into a governed adoption program, why payers are signaling "less PA" as a reputational and operating strategy, and why interoperability vendors are racing to prove CMS-0057 readiness - shifting the buyer question from "do you support FHIR?" to "can you run the workflow in production?"
From Policy Signal to Funded Operating Decision
A public-facing market brief on why Medicaid is moving toward explicit oversight for AI-enabled utilization workflows, CMS is turning electronic prior auth into a cross-ecosystem implementation program (not just a rule), and federal agencies are productizing consumer "front doors" that will reshape navigation, trust, and distribution.
Trust in Healthcare: Allocate Responsibility Before Automation
A public-facing market brief on why payers are reducing blanket prior auth while tightening data gates, CMS is turning GLP-1 affordability into a time-bound distribution rail, and states/regulators are drawing a hard line on AI experiences that look like practicing medicine.
Clinical Information and Distribution: Who Controls the Decision?
A public-facing market brief on why prior auth is becoming an API mandate, FDA is instrumenting itself with AI, and clinical "search" is turning into the next distribution channel - forcing founders to sell proof, not vibes.
Healthcare Integration: Where Control Justifies the Cost
A public-facing market brief on why CMS is forcing prior authorization into APIs, affordability is becoming time-bound GTM windows, and AI experiences are being boxed into clearer regulatory and workflow perimeters.
Drug Access, Patient AI and Data: Price the Unresolved Work
A public-facing market brief on why the next wave of healthtech winners will be the ones that treat affordability programs, AI care agents, and real-world data not as features, but as rails you can operate safely, measure, and sell against.
Prior Authorization Reform: Underwrite a Smaller, More Complex Workload
A public-facing market brief on how CMS ePrior Auth deadlines, payer simplification moves, and agency AI modernization are converging into a new commercialization test: workflow-native interoperability with provable access and admin lift.
Healthcare Technology Investment: Follow the Constraint and the Cash
A public-facing healthtech market brief on how AI, payer pressure, interoperability, value-based care, and access are converging into a new commercialization test for healthcare companies.
Payers Enter the AI-and-Access Era
I examine payer technology investments through case resolution, cost transfers, member access and the conditions under which operational gains become value.
The Orchestration Imperative
I examine orchestration as an investment in reliable care commitments, distinguishing information gaps from capacity, authority and funding failures.
CMS ACCESS Model and New York Healthcare
A New York ACCESS strategy built around accountable referral corridors, separate payment routes, clinical delivery capacity and cohort-level contribution economics.
Why New York Hospitals Are Building Digital Twins
Evaluate healthcare digital twins against simpler alternatives, response capacity, social-context validity and the incremental value of better decisions.
Game Theory, AI, Machine Learning, and LLMs
An incentive-based analysis of healthcare AI: counterparty responses, information asymmetry and contracts determine whether local productivity becomes system value.
Value-Based Care GTM
I connect value-based care commercialization to buyer risk, contract settlement, delivery obligations, evaluation horizons and the cash required to sustain care.
Specialty Pharmacy Commercialization
I examine specialty-pharmacy commercialization through therapy economics, payer access, working capital, operating controls and the durability of the asset.
Series A Healthtech GTM Strategy
I assess Series A healthtech growth through customer-cohort economics, implementation capacity, cash payback and the conditions for adding sales investment.
Provider Network Growth Strategy
I examine provider-network growth through referral economics, receiving capacity, concentration risk and the investment required to turn relationships into care.
Proof-Led Growth in Regulated Healthcare
I examine how healthcare companies sequence evidence and capital, test transferability and set defensible thresholds for deployment and commercial expansion.
Payer Strategy for Healthtech Founders
Payer commercialization through attribution, contracting economics and evidence: identify who retains the benefit and who funds its delivery.
HubSpot for Healthcare RevOps
Design HubSpot around accountable referral handoffs, authoritative systems and cohort economics that guide healthcare budget and staffing decisions.
Healthcare RevOps and Practical AI
Healthcare revenue operations: connect demand, completed services and collected contribution, then test where AI improves allocation.
Healthcare GTM Operating System
A healthcare growth framework linking customer cohorts, implementation capacity, collected contribution and working capital to the next allocation.
Healthcare AI Go-to-Market
Healthcare AI commercialization: align budget authority, implementation ownership and evidence of buyer value before scaling a repeatable offer.
Fractional Head of GTM for Healthcare
When fractional commercial leadership is worth funding: resolve market uncertainty, test repeatability and define the authority and timing of a permanent hire.
Claims Intelligence and Referral Leakage
A framework for separating observed referral leakage from recoverable demand, testing incremental contribution and allocating field resources against care capacity.
No articles match. Try another topic or search term.
Publication and review dates remain attached to each article. Dated market and policy analysis reflects its original evidence window; proposals, frameworks, and reported outcomes retain their original distinctions.
FROM EVIDENCE TO EXECUTIVE ACTION